Empagliflozin versus DPP4i or GLP-1RA for the risk of nephrolithiasis in patients with type 2 diabetes: Research letter from the EMPRISE cohort study.

Helen Tesfaye, Julie M Paik, Heidi Zakoul, Niklas Schmedt, Deborah J Wexler, Elisabetta Patorno

Abstract readLetter

In one paragraph

Article in Diabetes, obesity & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Helen TesfayeDivision of Pharmacoepidemiology, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0002-6264-2813

Julie M PaikDivision of Pharmacoepidemiology, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.

Heidi ZakoulDivision of Pharmacoepidemiology, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.

Niklas SchmedtBoehringer Ingelheim International GmbH, Ingelheim, Germany.

Deborah J WexlerMGH Diabetes Center, Division of Endocrinology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Elisabetta PatornoDivision of Pharmacoepidemiology, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0002-8809-9898

Funding

Novel approaches to improve comparative effectiveness research of medical and surgical weight reduction strategies in clinical practiceR01DK138036 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI Elisabetta Patorno · 2024 to 2026

$2.3M

Boehringer IngelheimFDA HHS U01 FD007213NIDDK NIH HHS R01 DK138036

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

antidiabetic drugDPP‐IV inhibitorempagliflozinGLP‐1 analoguepharmaco‐epidemiology

Identifiers

PMID40019137

DOI10.1111/dom.16303

PMCPMC12049256

What OpenQuestion holds

Textmetadata

LicenceTDM

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.